Puma Biotechnology, Inc. PBYI 深 滬
交易中 09-16 16:00:40 美东时间
2.50
-0.030
-1.19%
華盛通- 最 高2.5762
- 今 開2.52
- 成交量 34.87万股
- 最 低 2.45
- 昨 收 2.53
- 總市值 1.19亿
- 52周最高 7.73
- 市盈率 靜 5.51
- 換手率 0.73%
- 52周最低 2.13
- 委 比 -45.32%
- 總股本 4757.13万
- 歷史最高 279.37
- 量 比 1.17
- 振 幅 4.99%
- 歷史最低 1.60
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多反转！阿斯利康重磅抗癌药专利案最新进展
文章来源：药智网 图片来源：摄图网 免费领取药智数据VIP试用 https://vip.yaozh.com/introducemobile?tryout...
08-21 11:06
快讯 | 普玛生物技术公司 - 怀瑟申请补充赔偿，涵盖1月1日至裁决日期的违规行为。
Puma Biotechnology Inc - Wyeth Filed Motion Requesting Supplemental Damages for...
08-07 21:14
快讯 | 8月6日，法庭裁定阿斯利康未能证明惠氏声称的专利无效。
Puma Biotechnology- on Aug 6 Court Found AstraZeneca Had Not Proved Claim That ...
08-07 21:13
快讯 | Puma生物技术公司 - 阿斯利康已经提出动议挑战陪审团8月6日的裁决并请求新审判。
Puma Biotechnology Inc - AstraZeneca Has Filed a Motion Challenging Jury's Aug ...
08-07 21:13
Puma Biotechnology Sees Q3 Revenue $50M-$53M Vs $57.85M Est.; FY24 Revenue $183M-$190M Vs $217.63M Est.
Third Quarter and Full Year 2024 Financial Outlook Third Quarter 2024Full Year 2024Net Product Revenue$50 -53 million$183 - $190 millionRoyalty Revenue$20 - $22 million$30 - $33 millionLicense Revenue$0 million$1 -
08-02 05:38
Puma Biotechnology Q2 2024 Adj. EPS $(0.05) Beats $(0.13) Estimate, Sales $47.100M Beat $44.700M Estimate
Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.13) by 61.54 percent. The company reported quarterly sales of $47.100 million which beat
08-02 04:58
快讯 | 彪马生物科技公司 - 预计2024年净产品收入为1.83亿至1.9亿美元。
Puma Biotechnology Inc -Sees Full Year 2024 Net Product Revenue $183 - $190 Mil...
08-02 04:46
快讯 | Puma生物技术公司-预计2024年第三季度净产品收入为5000万美元-5300万
Puma Biotechnology Inc -Sees Third Quarter 2024 Net Product Revenue $50 Mln-53 ...
08-02 04:46
Where Puma Biotechnology Stands With Analysts
During the last three months, 5 analysts shared their evaluations of Puma Biote...
07-27 05:01
HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target
HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price target.
07-27 04:01
